Biogen cherry-picked data, got criticized, and now back cherry-picking some more. Here's a devastating quote from the article:

Quote:

---

There’s been a growing chorus of critics who say the data are increasingly clear that symptomatic patients can’t significantly benefit from any drug targeting amyloid beta. And that makes their big play on aducanumab increasingly risky.

---

https://endpts.com/biogen-eisai-fight-back-ag...over%20yet